These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
445 related articles for article (PubMed ID: 28244291)
21. Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941. Gaynon PS; Harris RE; Altman AJ; Bostrom BC; Breneman JC; Hawks R; Steele D; Zipf T; Stram DO; Villaluna D; Trigg ME J Clin Oncol; 2006 Jul; 24(19):3150-6. PubMed ID: 16717292 [TBL] [Abstract][Full Text] [Related]
22. Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse. Thomson B; Park JR; Felgenhauer J; Meshinchi S; Holcenberg J; Geyer JR; Avramis V; Douglas JG; Loken MR; Hawkins DS Pediatr Blood Cancer; 2004 Oct; 43(5):571-9. PubMed ID: 15382275 [TBL] [Abstract][Full Text] [Related]
23. Bortezomib, Dexamethasone, Mitoxantrone, and Vinorelbine (BDMV): An Active Reinduction Regimen for Children With Relapsed Acute Lymphoblastic Leukemia and Asparaginase Intolerance. Yeo KK; Gaynon PS; Fu CH; Wayne AS; Sun W J Pediatr Hematol Oncol; 2016 Jul; 38(5):345-9. PubMed ID: 27352191 [TBL] [Abstract][Full Text] [Related]
24. [Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol]. Liu X; Zou Y; Wang H; Chen X; Ruan M; Chen Y; Yang W; Guo Y; Liu T; Zhang L; Wang S; Zhang J; Liu F; Cai X; Qi B; Chang L; Zhu X Zhonghua Er Ke Za Zhi; 2014 Jun; 52(6):449-54. PubMed ID: 25190166 [TBL] [Abstract][Full Text] [Related]
25. Induction-consolidation with an idarubicin-containing regimen, unpurged marrow autograft, and post-graft chemotherapy in adult acute lymphoblastic leukaemia. Bassan R; Lerede T; Di Bona E; Rambaldi A; Rossi G; Pogliani E; Oriani A; D'Emilio A; Izzi T; Lambertenghi-Deliliers G; Corneo G; Barbui T Br J Haematol; 1999 Mar; 104(4):755-62. PubMed ID: 10192437 [TBL] [Abstract][Full Text] [Related]
26. Weekly polyethylene glycol conjugated L-asparaginase compared with biweekly dosing produces superior induction remission rates in childhood relapsed acute lymphoblastic leukemia: a Pediatric Oncology Group Study. Abshire TC; Pollock BH; Billett AL; Bradley P; Buchanan GR Blood; 2000 Sep; 96(5):1709-15. PubMed ID: 10961868 [TBL] [Abstract][Full Text] [Related]
27. ALL R-87 protocol in the treatment of children with acute lymphoblastic leukaemia in early bone marrow relapse. Giona F; Testi AM; Rondelli R; Amadori S; Arcese W; Meloni G; Moleti ML; Ceci A; Pillon M; Madon E; Comis M; Pession A; Mandelli F Br J Haematol; 1997 Dec; 99(3):671-7. PubMed ID: 9401083 [TBL] [Abstract][Full Text] [Related]
28. High-dose cytosine arabinoside and L-asparaginase in refractory acute lymphoblastic leukemia: the Children's Cancer Group experience. Harris RE; Sather HN; Feig SA Med Pediatr Oncol; 1998 Apr; 30(4):233-9. PubMed ID: 9473758 [TBL] [Abstract][Full Text] [Related]
29. Outcomes of patients with childhood B-cell precursor acute lymphoblastic leukaemia with late bone marrow relapses: long-term follow-up of the ALLR3 open-label randomised trial. Parker C; Krishnan S; Hamadeh L; Irving JAE; Kuiper RP; Révész T; Hoogerbrugge P; Hancock J; Sutton R; Moorman AV; Saha V Lancet Haematol; 2019 Apr; 6(4):e204-e216. PubMed ID: 30826273 [TBL] [Abstract][Full Text] [Related]
30. [Preliminary results of BFM 96 protocol in treatment of childhood ALL relapse in the experience of the Polish Paediatric Leukaemia /Lymphoma Study Group]. Chybicka A; Bogusławska-Jaworska J; Gorczyńska E; Armata J; Balcerska A; Balwierz W; Bubala H; Filiks-Litwin B; Kołecki P; Kowalczyk J; Łukowska K; Matysiak M; Rokicka-Milewska R; Rola-Kurc E; Stencel D; Sonta-Jakimczyk D; Strojny W; Wachowiak J; Wieczorek M; Wysocki M; Zelenay E Med Wieku Rozwoj; 2000; 4(1 Suppl 2):43-8. PubMed ID: 12021461 [TBL] [Abstract][Full Text] [Related]
31. Survival outcome following isolated central nervous system relapse treated with additional chemotherapy and craniospinal irradiation in childhood acute lymphoblastic leukemia. Kumar P; Kun LE; Hustu HO; Mulhern RK; Hancock ML; Coffey D; Rivera GK Int J Radiat Oncol Biol Phys; 1995 Feb; 31(3):477-83. PubMed ID: 7852109 [TBL] [Abstract][Full Text] [Related]
32. A single high dose of idarubicin combined with high-dose ARA-C (MSKCC ALL-3 protocol) in adult and pediatric patients with acute lymphoblastic leukemia. Experience at the University "La Sapienza" of Rome. Testi AM; Moleti ML; Giona F; Annino L; Chiaretti S; Del Giudice I; Todisco E; D'Elia G; Ferrari A; Arcese W; Mandelli F Haematologica; 1997; 82(6):664-7. PubMed ID: 9499665 [TBL] [Abstract][Full Text] [Related]
33. Treatment of occult or late overt testicular relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study. Wofford MM; Smith SD; Shuster JJ; Johnson W; Buchanan GR; Wharam MD; Ritchey AK; Rosen D; Haggard ME; Golembe BL J Clin Oncol; 1992 Apr; 10(4):624-30. PubMed ID: 1548525 [TBL] [Abstract][Full Text] [Related]
34. Remission Rate of Acute Lymphoblastic Leukemia (ALL) in Adolescents and Young Adults (AYA). Vallacha A; Haider G; Raja W; Kumar D J Coll Physicians Surg Pak; 2018 Feb; 28(2):118-121. PubMed ID: 29394970 [TBL] [Abstract][Full Text] [Related]
35. Case-control analysis of allogeneic bone marrow transplantation versus maintenance chemotherapy for relapsed ALL in children. Hoogerbrugge PM; Gerritsen EJ; vd Does-van den Berg A; vd Berg H; Zwinderman AH; Hermans J; Vossen JM Bone Marrow Transplant; 1995 Feb; 15(2):255-9. PubMed ID: 7773215 [TBL] [Abstract][Full Text] [Related]
36. Peripheral blast counts at diagnosis of late isolated bone marrow relapse of childhood acute lymphoblastic leukemia predict response to salvage chemotherapy and outcome. Berlin-Frankfurt-Münster Relapse Study Group. Bührer C; Hartmann R; Fengler R; Rath B; Schrappe M; Janka-Schaub G; Henze G J Clin Oncol; 1996 Oct; 14(10):2812-7. PubMed ID: 8874343 [TBL] [Abstract][Full Text] [Related]
37. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia. Results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. Veerman AJ; Hählen K; Kamps WA; Van Leeuwen EF; De Vaan GA; Solbu G; Suciu S; Van Wering ER; Van der Does-Van der Berg A J Clin Oncol; 1996 Mar; 14(3):911-8. PubMed ID: 8622039 [TBL] [Abstract][Full Text] [Related]
38. Outcome of adult acute lymphoblastic leukemia with BFM protocol in a resource-constrained setting. Malhotra P; Varma S; Varma N; Kumari S; Das R; Jain S; Ahluwalia J; Mahi S; Sharma SC; Radhika S Leuk Lymphoma; 2007 Jun; 48(6):1173-8. PubMed ID: 17577781 [TBL] [Abstract][Full Text] [Related]
39. Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical study. Bassan R; Pogliani E; Lerede T; Fabris P; Rossi G; Morandi S; Casula P; Lambertenghi-Deliliers G; Vespignani M; Izzi T; Coser P; Corneo G; Barbui T Haematologica; 1999 Dec; 84(12):1088-93. PubMed ID: 10586210 [TBL] [Abstract][Full Text] [Related]
40. FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study. Hashmi KU; Khan B; Ahmed P; Raza S; Hussain I; Mahmood A; Iqbal H; Malik HS; Anwar M J Pak Med Assoc; 2005 Jun; 55(6):234-8. PubMed ID: 16045091 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]